Rezolute Receives FDA Recommendation for Pre-BLA Meeting for Ersodetug

Filing content

Despite the Phase 3 sunRIZE study failing to meet primary endpoints, the FDA recommended a pre-BLA meeting as a precursor to submitting a Biologics License Application.